Absci · 公司档案

公开已核验进展

1. Absci 公布 AI 设计抗体 ABS-201 的 II 期试验初步计划

   Thu Sep 24 2026 12:00:49 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据

   据 Absci 官方公告，AI 设计抗体 ABS-201 的 II 期试验预计于 2027 年中启动。当前披露为初步计划，不能写成 II 期已经开展。

   Absci

   核查事件证据 →

合作、许可与并购时间线

当前显示的公开进展中没有合作、许可或并购节点；这不代表该公司从未发生相关活动。

以上来自最新 1 条已核验进展。合作事件成立与模型效果、实验结果或临床进度分别需要证据。

公开原文线索

• Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

  Absci official news RSS · 行业原文收录 · 来源发布：Thu Sep 24 2026 12:00:49 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER

  原始出处

• Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

  Absci official news RSS · 行业原文收录 · 来源发布：Tue Jul 14 2026 20:05:30 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announc

  原始出处

• Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

  Absci official news RSS · 行业原文收录 · 来源发布：Wed Jun 24 2026 10:30:27 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval o

  原始出处

• Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

  Absci official news RSS · 行业原文收录 · 来源发布：Thu Apr 23 2026 20:04:58 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announ

  原始出处

已验证的官方与订阅来源

• Absci official news RSS · 采集已启用 · 最近成功 Thu Oct 08 2026 14:07:24 GMT+0000 (Coordinated Universal Time)

来源验证与持续采集分别显示；原文收录不自动成为已核验事件。